{
  "abstract": "Background: Primary central nervous system lymphoma (PCNSL) is a rare, aggressive malignant tumor with poor prognosis, and the optimal standard treatment remains undefined. This study aimed to compare the efficacy and safety of rituximab, high-dose methotrexate plus temozolomide (RMT regimen) and orelabrutinib plus RMT (RMOT regimen) in patients with newly diagnosed PCNSL.\n\nMethods: This retrospective study enrolled adult patients with histologically confirmed PCNSL who had received induction treatment with the RMT regimen or the novel combination regimen of orelabrutinib. Progression-free survival (PFS) and overall survival (OS) were analyzed using Cox proportional hazards models. Propensity score matching (PSM) was performed to balance baseline characteristics between the treatment groups.\n\nResults: A total of 101 patients were included in the analysis. The median age was 59 years, and most were of the non-germinal center B-cell (non-GCB) subtype (62.4%) and deep structural involvement (64.4%). The RMOT group was associated with a higher complete response rate than the RMT group (84.8% vs 63.2%, P = .026) and had superior PFS (HR 0.357, 95% CI 0.150-0.850, P = .015). These benefits remained after PSM. RMOT regimen was associated with significantly longer PFS in patients with the non-GCB subtype (HR 0.274, 95% CI 0.081-0.932, P = .027). Adverse events were primarily grade 1-2, and no treatment-related deaths occurred in either group.\n\nConclusions: This retrospective study suggested that RMOT was associated with higher CRR and longer PFS compared to RMT, particularly in non-GCB subtype patients, with a tolerable safety profile, and has the potential to become a new optional regimen for clinical practice.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "name": "Peng Zhang",
      "orcid": "0009-0000-3667-5753"
    },
    {
      "name": "Man Nie"
    },
    {
      "name": "Hang Yang"
    },
    {
      "name": "Xiaojie Fang"
    },
    {
      "name": "Chengxi He"
    },
    {
      "name": "Dongyu Zhuang"
    },
    {
      "name": "Honglian Liu"
    },
    {
      "name": "Silan Huang"
    },
    {
      "name": "Dexin Lei"
    },
    {
      "name": "Qingqing Cai"
    },
    {
      "name": "Yi Xia",
      "orcid": "0009-0003-1526-1043"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4jeyxvas80nyw.bib",
  "cited_by": 0,
  "doi": "10.1093/noajnl/vdag262",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13711460/",
  "id": "4jeyxvas80nyw",
  "issns": [
    "2632-2498"
  ],
  "landing_url": "https://doi.org/10.1093/noajnl/vdag262",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "AcademicSubjects/MED00300"
    ],
    [
      "heading",
      "AcademicSubjects/MED00310"
    ],
    [
      "heading",
      "Clinical Investigations"
    ],
    [
      "openalex",
      "2728|CNS Lymphoma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7221607531",
  "pdf_url": null,
  "pmcid": "PMC13711460",
  "pmid": "42948599",
  "published": "2026-10-12",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/4jeyxvas80nyw.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:22:14Z",
      "native_id": "PMC13711460",
      "source": "pmc",
      "url": "https://doi.org/10.1093/noajnl/vdag262"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|CNS Lymphoma Diagnosis and Treatment",
      "subfield": "neurology"
    }
  ],
  "title": "Improved efficacy of orelabrutinib plus rituximab, temozolomide and high-dose methotrexate versus rituximab, high-dose methotrexate plus temozolomide in untreated primary CNS lymphoma: A matched analysis",
  "title_text": "Improved efficacy of orelabrutinib plus rituximab, temozolomide and high-dose methotrexate versus rituximab, high-dose methotrexate plus temozolomide in untreated primary CNS lymphoma: A matched analysis",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:22:14Z",
  "url": "https://research.draconitic.com/paper/4jeyxvas80nyw",
  "venue": "Neuro-Oncology Advances",
  "versions": []
}